指南与共识泌尿男性生殖肿瘤

中国前列腺癌睾酮管理专家共识(2026版)

[Chinese expert consensus on prostate cancer testosterone management (2026 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

中国前列腺癌发病率逐年上升,2022年位列男性恶性肿瘤第6位,晚期患者占比高、病死率高。雄激素剥夺治疗(ADT)是晚期前列腺癌治疗基石,睾酮是ADT疗效监测的关键指标。本共识推荐睾酮<50 ng/dL为去势标准,深度降酮至<20 ng/dL可作为改善预后的参考指标,并规范了睾酮检测方法与全程监测频率。

要点

  • 共识推荐睾酮<50 ng/dL为去势标准,深度降酮至<20 ng/dL可作为改善预后的参考指标。
  • 睾酮监测应贯穿诊疗全程:基线、前6个月每月、稳定后3年内每3个月、之后每6个月。
  • PSA不能替代睾酮评估ADT疗效,两者无线性相关性,应结合两者指导个体化决策。

核心结论

  • ADT是晚期前列腺癌治疗基石,应贯穿治疗全周期,睾酮管理对实现ADT精细化管理目标和改善预后具有重要意义。
  • 共识推荐睾酮<50 ng/dL为去势标准,深度降酮至<20 ng/dL可作为改善患者预后的参考指标。
  • PSA无法直接替代睾酮水平评估ADT疗效,两者无线性相关性,应结合两者检测结果指导个性化治疗决策。

研究设计与样本

  • 本文件为《中国前列腺癌睾酮管理专家共识(2026版)》,由中国专家制定,全文以中文发表于《中华肿瘤杂志》。
  • 共识基于中国前列腺癌疾病负担与ADT治疗现状,对睾酮检测方法、监测频率及全程管理提出推荐。

主要发现

  • 2022年数据示中国前列腺癌发病率位列男性恶性肿瘤第6位,新发病例中晚期患者占比高、病死率高。
  • 放射性免疫分析法、化学发光免疫分析法及液相色谱-质谱联用法均为可及的睾酮检测手段。
  • 有条件可采用分步检测法监测睾酮,以提高敏感性、精确性及稳定性。

关键数值与推荐

  • 推荐睾酮水平<50 ng/dL为去势标准。
  • 深度降酮即睾酮水平抑制到<20 ng/dL的更低水平,可作为改善患者预后的参考指标。
  • ADT开始前检测基线睾酮水平;治疗开始后前6个月每月监测。
  • 病情稳定后3年内每3个月检测1次,3年后每6个月检测1次。
  • 新辅助治疗、辅助治疗起始、生化复发及转移性去势敏感性前列腺癌等关键阶段患者更需重视睾酮监测。

临床怎么用

  • ADT全周期应同步关注睾酮与PSA监测,不能以PSA直接替代睾酮评估ADT疗效。
  • 按共识推荐的频率维持合理睾酮检测,结合两项结果及时发现睾酮逃逸、确认去势抵抗状态。
  • 检测结果可为治疗切换提供依据,以改善患者生存获益和生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of prostate cancer in China is increasing year by year. Data from 2022 indicate that its incidence ranks sixth among male malignant tumors, with a high proportion of advanced-stage patients and high mortality rate among new cases each year, leading to a continuously increasing disease burden. Androgen deprivation therapy (ADT) has been the cornerstone of treatment for advanced prostate cancer since its establishment in 1941. Whether as monotherapy or in combination with novel endocrine therapeutic agents, ADT-based regimens should be maintained throughout the entire treatment course of advanced prostate cancer. Testosterone is a critical biomarker for monitoring the efficacy of ADT, and testosterone management is of great significance in achieving refined ADT goals and improving patient prognosis. This consensus recommends a testosterone level of >50 ng/dL as the castration standard. On this basis, deep testosterone suppression, defined as reducing testosterone levels to below 20 ng/dL, may serve as a reference indicator for improving patient prognosis. Regarding testosterone measurement, radioimmunoassay (RIA), chemiluminescence immunoassay (CLIA), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are all available methods. Considering the balance between cost and efficiency, this consensus recommends that a stepwise testing approach for testosterone monitoring be adopted if conditions permit, to improve sensitivity, accuracy, and stability. Testosterone monitoring should be performed throughout the entire process of prostate cancer diagnostic and treatment. Baseline level should be measured before ADT initiation; monitoring should be performed monthly for the first 6 months of treatment; after disease stabilization, every 3 months for the first 3 years, and every 6 months thereafter. Patients in critical phases such as neoadjuvant therapy, initiation of adjuvant therapy, biochemical recurrence, and metastatic castration-sensitive prostate cancer require particular attention to testosterone surveillance. In the whole-process management of prostate cancer diagnosis and treatment, attention should be paid to testosterone monitoring alongside prostate-specific antigen (PSA) surveillance. PSA cannot directly replace testosterone levels in evaluating ADT efficacy, as there is no linear correlation between the two parameters. Maintaining an appropriate frequency of testosterone testing and using the results of both tests to guide personalized therapeutic decisions can facilitate timely detection of testosterone escape and confirmation of castration-resistant status, provide evidence for treatment switching, and ultimately improve patient survival benefits and quality of life. 中国前列腺癌发病率逐年上升,2022年数据显示其发病率已位列中国男性恶性肿瘤第6位,且每年新发病例中晚期患者占比高、病死率高,疾病负担持续加重。雄激素剥夺治疗(ADT)自1941年确立以来始终是晚期前列腺癌治疗的基石,无论是基础的单药或联合新型内分泌治疗药物方案均应贯穿晚期前列腺癌治疗全周期。睾酮是ADT疗效监测的关键指标,睾酮管理对实现ADT精细化管理目标、改善患者预后具有重要意义。共识推荐睾酮水平<50 ng/dl为去势标准,在此基础上,深度降酮即将睾酮水平抑制到<20 ng/dl的更低水平可作为改善患者预后的参考指标。在睾酮水平检测方面,放射性免疫分析法、化学发光免疫分析法及液相色谱-质谱联用法均为可及的检测手段。考虑到成本与效能的平衡,建议有条件可采用分步检测法监测睾酮,以提高敏感性、精确性及稳定性。睾酮监测应贯穿前列腺癌诊疗全程,ADT开始前需检测基线水平,治疗开始后前6个月应每月监测,病情稳定后3年内每3个月检测1次,3年后每6个月检测1次;处于新辅助治疗、辅助治疗起始、生化复发及转移性去势敏感性前列腺癌等关键阶段的患者,更需重视睾酮监测。前列腺癌诊疗全程管理中,关注前列腺特异性抗原(PSA)的同时应重视睾酮监测。PSA无法直接替代睾酮水平评估ADT疗效,两者无线性相关性。维持合理的睾酮检测频率,结合两者检测结果指导个性化治疗决策,可及时发现睾酮逃逸、确认去势抵抗状态等,为治疗切换提供依据,最终提高患者生存获益和生活质量。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on prostate cancer testosterone management (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42199083. doi:10.3760/cma.j.cn112152-20260106-00008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。